Cymabay Therapeutics Inc
(CBAY)
8.260.46(5.83%)
12:45:20 PM- IEX real time price
Open
7.88
High
N/A
Low
N/A
Close
8.255
1.67
52 Week Range
4.74
 
 
 
 
 
1.67
52 Week Range
4.74
 
 
 
 
 
1.67
52 Week Range
4.74
 
 
 
 
 

Company Profile

Cymabay Therapeutics Inc

7575 Gateway Blvd Ste 110Newark, California 94560-1194

15102938800

SECTOR
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
FISCAL YEAR END
1.67 - 4.74
REVENUE
1.67
NET INCOME
1.67 - 4.74
2021 SALES GROWTH
1.67
EMPLOYEES
44.00

Cymabay Therapeutics Inc

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay is developing seladelpar, a potent, selective, orally active PPARδ agonist for patients with primary biliary cholangitis (PBC). Seladelpar has received an orphan designation from the US Food and Drug administration (FDA) and the European Medicine Agency (EMA). Seladelpar also received Breakthrough Therapy Designation from the FDA for early stage PBC and PRIority MEdicines status from the EMA. CymaBay is currently commencing a global, Phase 3 registration study of seladelpar for PBC. This study is a 52-week, placebo-controlled, randomized, phase 3 study to evaluate the safety and efficacy of seladelpar (RESPONSE) in patients with PBC.